Opinion
Video
Limitations on Optimal Biomarker Testing Rates
A panel of experts discuss the current limitations of optimal biomarker testing rates in the community.
EP: 1.Biomarker Testing and Guideline-Recommended Care in mNSCLC
EP: 2.Strategies to Increase Biomarker Testing Rates
Now Viewing
EP: 3.Limitations on Optimal Biomarker Testing Rates
EP: 4.Impact of Biomarker Testing on Treatment Selection and Outcomes
EP: 5.Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC
EP: 6.NCCN Recommendations by PD-L1 Expression Level
EP: 7.Limitations of NCCN PD-L1 Expression Recommendations
EP: 8.Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC
EP: 9.Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC
EP: 10.Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response
EP: 11.Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection
EP: 12.Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches
EP: 13.Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations
Video content above is prompted by the following:
- What may currently limit optimal biomarker testing rates in the community?
Related Videos
Related Content
